Literature DB >> 14505077

Formation of platinated GG cross-links on DNA by photoactivation of a platinum(IV) azide complex.

Jana Kaspárková1, Fiona S Mackay, Viktor Brabec, Peter J Sadler.   

Abstract

Platinum(II) diam(m)ine complexes such as cisplatin are effective anticancer drugs but have accompanying side effects. We are exploring the design of platinum complexes with low toxicity that could be photoactivated selectively at the target site. We show here that the Pt(IV) azide complex cis, trans-[Pt(en)(N(3))(2)(OH)(2)] is unreactive towards DNA until irradiated with visible light. Transcription mapping studies of a 212-bp fragment of pSP73KB plasmid DNA treated with cis, trans-[Pt(en)(N(3))(2)(OH)(2)] and irradiated with visible light showed that the platination sites were similar to those observed for cisplatin, and were mainly in GG sequences. HPLC analysis of enzymatic digests of an irradiated sample of a 40-bp DNA duplex treated with the same complex also revealed preferential formation of GG cross-links. Since such DNA lesions are thought to be responsible for the induction of apoptosis in cancer cells by platinum drugs, the use of unreactive photoactivatable platinum pro-drugs may become an effective strategy for the design of a new generation of platinum anticancer complexes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14505077     DOI: 10.1007/s00775-003-0474-3

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  13 in total

1.  Effect of geometric isomerism in dinuclear platinum antitumor complexes on DNA interstrand cross-linking.

Authors:  J Kaspárková; O Nováková; O Vrána; N Farrell; V Brabec
Journal:  Biochemistry       Date:  1999-08-24       Impact factor: 3.162

2.  Structure, Recognition, and Processing of Cisplatin-DNA Adducts.

Authors:  E R Jamieson; S J Lippard
Journal:  Chem Rev       Date:  1999-09-08       Impact factor: 60.622

3.  Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia.

Authors:  M A Barry; C A Behnke; A Eastman
Journal:  Biochem Pharmacol       Date:  1990-11-15       Impact factor: 5.858

4.  DNA interactions of bifunctional dinuclear platinum(II) antitumor agents.

Authors:  R Zaludová; A Zákovská; J Kasparková; Z Balcarová; V Kleinwächter; O Vrána; N Farrell; V Brabec
Journal:  Eur J Biochem       Date:  1997-06-01

Review 5.  The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes.

Authors:  A Eastman
Journal:  Pharmacol Ther       Date:  1987       Impact factor: 12.310

6.  Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine)platinum(II).

Authors:  A Eastman
Journal:  Biochemistry       Date:  1983-08-02       Impact factor: 3.162

7.  Interstrand cross-links are preferentially formed at the d(GC) sites in the reaction between cis-diamminedichloroplatinum (II) and DNA.

Authors:  M A Lemaire; A Schwartz; A R Rahmouni; M Leng
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

8.  Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA.

Authors:  A Eastman
Journal:  Biochemistry       Date:  1986-07-01       Impact factor: 3.162

9.  Photolysis of an iodoplatinum(IV) diamine complex to cytotoxic species by visible light.

Authors:  N A Kratochwil; P J Bednarski; H Mrozek; A Vogler; J K Nagle
Journal:  Anticancer Drug Des       Date:  1996-03

10.  DNA interstrand cross-links of trans-diamminedichloroplatinum(II) are preferentially formed between guanine and complementary cytosine residues.

Authors:  V Brabec; M Leng
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

View more
  10 in total

1.  Pt-bridges in various single-strand and double-helix DNA sequences. DFT and MP2 study of the cisplatin coordination with guanine, adenine, and cytosine.

Authors:  Matej Pavelka; Jaroslav V Burda
Journal:  J Mol Model       Date:  2006-09-20       Impact factor: 1.810

Review 2.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

Authors:  Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard
Journal:  Chem Rev       Date:  2016-02-11       Impact factor: 60.622

3.  Trans,trans,trans-[PtIV(N3)2(OH)2(py)(NH3)]: a light-activated antitumor platinum complex that kills human cancer cells by an apoptosis-independent mechanism.

Authors:  Aron F Westendorf; Julie A Woods; Katharina Korpis; Nicola J Farrer; Luca Salassa; Kim Robinson; Virginia Appleyard; Karen Murray; Renate Grünert; Alastair M Thompson; Peter J Sadler; Patrick J Bednarski
Journal:  Mol Cancer Ther       Date:  2012-06-18       Impact factor: 6.261

Review 4.  Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs.

Authors:  Jingjing Huang; Weize Ding; Xingfan Zhu; Bingbing Li; Fangang Zeng; Kui Wu; Xiaoqin Wu; Fuyi Wang
Journal:  Front Chem       Date:  2022-06-09       Impact factor: 5.545

5.  Photoinduced reactions of cis,trans,cis-[Pt(IV)(N3)2(OH)2(NH3)2) with 1-methylimidazole.

Authors:  Hazel I A Phillips; Luca Ronconi; Peter J Sadler
Journal:  Chemistry       Date:  2009       Impact factor: 5.236

6.  A potent cytotoxic photoactivated platinum complex.

Authors:  Fiona S Mackay; Julie A Woods; Pavla Heringová; Jana Kaspárková; Ana M Pizarro; Stephen A Moggach; Simon Parsons; Viktor Brabec; Peter J Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-19       Impact factor: 11.205

Review 7.  Unusual DNA binding modes for metal anticancer complexes.

Authors:  Ana M Pizarro; Peter J Sadler
Journal:  Biochimie       Date:  2009-04-01       Impact factor: 4.079

8.  Comparison of the electronic properties, and thermodynamic and kinetic parameters of the aquation of selected platinum(II) derivatives with their anticancer IC50 indexes.

Authors:  Ondrej Bradác; Tomás Zimmermann; Jaroslav V Burda
Journal:  J Mol Model       Date:  2008-03-06       Impact factor: 1.810

9.  Controlling Platinum, Ruthenium and Osmium Reactivity for Anticancer Drug Design.

Authors:  Pieter C A Bruijnincx; Peter J Sadler
Journal:  Adv Inorg Chem       Date:  2009-07-07       Impact factor: 3.282

10.  Investigations of the binding of [Pt2(DTBPA)Cl2](II) and [Pt2(TPXA)Cl2](II) to DNA via various cross-linking modes.

Authors:  Hongwei Yue; Bo Yang; Yan Wang; Guangju Chen
Journal:  Int J Mol Sci       Date:  2013-09-26       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.